NCT06994676 2026-03-16
CROSSCHECK-001
Crossbow Therapeutics, Inc.
Phase 1 Recruiting
Clinical Trials
37 trialsNCT06950034 2026-02-09
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
Solu Therapeutics, Inc
Phase 1 Recruiting
NCT05787496 2026-01-28
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
NextCure, Inc.
Phase 1 Terminated
NCT04937166 2025-11-10
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
Kahr Medical
Phase 1 Terminated
NCT04609826 2025-10-01
DHODH
Janssen Research & Development, LLC
Phase 1 Completed
NCT05209152 2025-07-14
AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
Amgen
Phase 1 Terminated
NCT04891757 2025-07-10
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
Foghorn Therapeutics Inc.
Phase 1 Active not recruiting
NCT04603001 2025-06-27
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
NCT05038800 2025-05-21
MK-0482-002
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT03066648 2025-05-18
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Novartis
Phase 1 Completed
NCT06462365 2025-04-15
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Tr1X, Inc.
Phase 1 Recruiting
NCT04041050 2025-02-14
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
AbbVie
Phase 1 Active not recruiting
NCT05488548 2025-01-14
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
Epigenetix, Inc.
Phase 1 Recruiting
NCT03814005 2024-09-05
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
Takeda
Phase 1 Completed
NCT03813186 2024-08-02
Effect of Food on Blood Levels of ASTX727
Astex Pharmaceuticals, Inc.
Phase 1 Completed
NCT04155580 2024-08-02
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Astex Pharmaceuticals, Inc.
Phase 1 Terminated
NCT04637009 2024-08-02
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
Astex Pharmaceuticals, Inc.
Phase 1 Terminated
NCT02841540 2024-02-14
Encore-MDS
Hemavant Sciences GmbH
Phase 1 Terminated
NCT05641259 2024-02-02
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1 Unknown
NCT05107856 2024-01-31
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Prelude Therapeutics
Phase 1 Terminated
NCT05048498 2023-10-17
Pharmacokinetics, Tolerability and Safety of NEX-18a
Nanexa AB
Phase 1 Completed
NCT05456269 2023-10-03
BISECT
Race Oncology Ltd
Phase 1 Withdrawn
NCT05970822 2023-08-01
Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML
Biocity Biopharmaceutics Co., Ltd.
Phase 1 Unknown
NCT03886831 2023-03-28
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
Prelude Therapeutics
Phase 1 Completed
NCT03404726 2022-01-11
A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies
Bayer
Phase 1 Terminated
NCT03263637 2021-10-22
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies
AstraZeneca
Phase 1 Completed
NCT01613976 2020-12-19
A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients
Novartis
Phase 1 Completed
NCT04272957 2020-06-16
A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms
Hutchmed
Phase 1 Unknown
NCT02546284 2020-02-28
Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)
Humanigen, Inc.
Phase 1 Completed
NCT00761722 2019-11-08
RACE
Celgene
Phase 1 Completed
NCT02201329 2018-07-30
Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Boehringer Ingelheim
Phase 1 Completed
NCT00642031 2016-08-09
Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies
Prescient Therapeutics, Ltd.
Phase 1 Completed
NCT01398462 2016-03-08
Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
JW Pharmaceutical
Phase 1 Completed
NCT00664677 2016-02-23
Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia
Erimos Pharmaceuticals
Phase 1 Terminated
NCT01908387 2015-07-28
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
Celgene
Phase 1 Terminated
NCT00283114 2014-12-18
A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Seagen Inc.
Phase 1 Completed
NCT00004047 2012-05-16
Chemotherapy in Treating Patients Who Have Hematologic Cancer
Daiichi Sankyo
Phase 1 Completed